Breast and cervical cancer together represent a paradox in global health: both are increasingly understood at the molecular and biological level, yet outcomes remain deeply shaped by when disease is detected and how care is delivered. While cervical cancer is largely preventable through early screening, millions of women still lack access to reliable detection. In breast cancer, effective treatments exist, but uncertainty in predicting response and recurrence often leads to overtreatment or missed opportunities for early intervention. Addressing these challenges requires more than better drugs or diagnostics: it demands integrated systems that connect technology, biology, and real-world care.

 

Our research program brings engineering, translational science, and global health together to redesign how breast and cervical cancer are detected and treated across diverse settings. We develop scalable screening technologies that move detection out of hospitals and into communities and homes, using low-cost imaging, artificial intelligence, and digital health platforms to expand access and improve decision-making. In parallel, we engineer therapies and imaging tools that reshape the tumor environment and reveal early signs of relapse, enabling safer immune activation and more precise treatment strategies. Our work focuses on shifting cancer care earlier, reducing unnecessary intervention, and ensuring that advances in technology translate into equitable, real-world impact.